Best Ruchit Podcasts (2026)

1
Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers 22:54

Play Pause

7d ago22:54

22:54

Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak (Division of Cancer Prevention and Control, The Ohio State University) and Dr Marissa Baker (Department of Environmental & Occupational Health Science, University of Washington School of Public Health) to discuss their population-based study analysing cancer mortality r…

1
In conversation with... Jesse Plascak and Marissa Baker 23:00

8d ago23:00

23:00

Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak and Dr Marissa Baker to discuss their population-based study analysing cancer mortality rates by sex, cancer type, and occupation type among working-age adults in the USA.By The Lancet

1
Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3 25:41

1M ago25:41

25:41

Dr Andre Pfob (Department of Obstetrics & Gynecology, Heidelberg University Hospital) and Prof Peter Dubsky (Faculty of Health Sciences and Medicine, University of Lucerne) discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consen…

1
In conversation with... Andre Pfob and Peter Dubsky 25:41

1M ago25:41

25:41

Dr Andre Pfob and Prof Peter Dubsky discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus.By The Lancet

1
Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission 10:46

2M ago10:46

10:46

Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care. Click here to read the full Commission: The human crisis in cancer: a Lancet Oncology Commission And comment: Re-establishing human-centred care Tell us what …

1
In conversation with... Gary Rodin 10:46

2M ago10:46

10:46

Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care.By The Lancet

1
Matthias Preusser on the phase 2 TUXEDO-3 trial 17:10

2M ago17:10

17:10

Deputy Editor Ali Landman speaks with Matthias Preusser (Medical University of Vienna, Vienna, Austria) about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer. Hear about the potential of HER3-targeted antibody-drug conj…

1
In conversation with... Matthias Preusser 17:00

2M ago17:00

17:00

Deputy Editor Ali Landman speaks with Matthias Preusser about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer.By The Lancet

1
Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer 12:15

3M ago12:15

12:15

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to discuss his SunRISe4-trial published in our October issue. Effective treatments are needed for patie…

1
In conversation with... Andrea Necchi 12:15

3M ago12:15

12:15

Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, discusses his SunRISe4-trial published in our October issue.By The Lancet

1
Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas 14:22

4M ago14:22

14:22

Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two exciting papers on TERT expression and TERT promoter mutations in meningiomas. In these two cohort studies, the authors analyse the expres…

1
In conversation with... Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, & Matija Snuderl 14:22

4M ago14:22

14:22

Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two exciting papers on TERT expression and TERT promoter mutations in meningiomas.By The Lancet

1
In conversation with... Jinming Li 7:36

5M ago7:36

7:36

Jinming Li discusses his international, multicohort, observational study on patterns in genomic mutations among patients with early-onset colorectal cancer.By The Lancet

1
Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer 7:36

5M ago7:36

7:36

Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Dr Jinming Li, from the Department of Colorectal Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China to discuss his international, multicohort, observational study on patterns in genomic mutations among patients with early-onset colorectal cancer. Read the full article:…

1
In conversation with... Abdalla Awidi 8:22

7M ago8:22

8:22

Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Professor Abdalla Awidi (Founder and Director of Stem Cell Therapy Center, University of Jordan, Amman, Jordan) to discuss The Lancet Oncology's Cancer control in the Middle East Series. The Series comprises five papers from regional experts who discuss the current outlook for cancer …

1
Abdalla Awidi on cancer control in the Middle East 8:22

7M ago8:22

8:22

Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Professor Abdalla Awidi (Founder and Director of Stem Cell Therapy Center, University of Jordan, Amman, Jordan) to discuss The Lancet Oncology's Cancer control in the Middle East Series. The Series comprises five papers from regional experts who discuss the current outlook for cancer …

1
ASCO 2025 Debrief 14:45

7M ago14:45

14:45

Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to list…

1
In conversation with... Caroline Robert 10:45

7M ago10:45

10:45

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial on the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors in patients with metastatic melanoma with BRAFV600E or BRAFV600K mutations.…

1
Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial) 10:45

7M ago10:45

10:45

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial. EBIN was an open-label, randomised, controlled, phase 2 trial conducted at 37 centres in eight European countries, and aimed to investigate the use of a targeted-therapy induction regimen …

1
Richard Bryant on transperineal vs transrectal biopsy for prostate cancer 18:02

8M ago18:02

18:02

Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Richard Bryant from the University of Oxford to discuss the TRANSLATE trial. This extensive UK-based randomised controlled trial compares the use of local anaesthetic ultrasound-guided transperineal biopsy with the traditional transrectal biopsy approach for diagnosing p…

1
In conversation with... Richard Bryant 18:02

8M ago18:02

18:02

Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Richard Bryant from the University of Oxford to discuss the TRANSLATE trial on transperineal vs transrectal biopsy for prostate cancer.By The Lancet

1
In conversation with... Amar U. Kishan 7:33

9M ago7:33

7:33

Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium.By The Lancet

1
Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA) 7:33

9M ago7:33

7:33

Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium. Read the full article: https://www.thelancet.com/journals/lanonc/article…

1
Ariana Znaor on cancer surveillance in the Eastern Mediterranean region 20:03

10M ago20:03

20:03

Ariana Znaor (Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France) discusses her Review on cancer surveillance in the Eastern Mediterranean Region: a 10-year IARC-WHO EMRO collaboration. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://thelancet.bsky.so…

1
In conversation with... Ariana Znaor on cancer surveillance 20:03

10M ago20:03

20:03

Ariana Znaor (Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France) discusses her Review on cancer surveillance in the Eastern Mediterranean Region: a 10-year IARC-WHO EMRO collaboration.By The Lancet

1
In conversation with... Ian Tannock 18:03

11M ago18:03

18:03

Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical trials.By The Lancet

1
Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials 18:03

11M ago18:03

18:03

Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical trials. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... h…

1
Yannick Romero on the changing landscape of national cancer control plans 24:40

1y ago24:40

24:40

Dr Yannick Romero (Union for International Cancer Control) discusses his Policy Review on the changing landscape of the national cancer control plans and his work with the international cancer control partnership. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00405-4/fulltext?dgcid=buzzsprout_icw_podcast_…

1
In conversation with... Yannick Romero 24:48

1y ago24:48

24:48

Dr Yannick Romero (Union for International Cancer Control) discusses his Policy Review on the changing landscape of the national cancer control plans and his work with the international cancer control partnership.By The Lancet

1
In conversation with... M Saiful Huq and Mostafa Aziz Sumon 22:15

1y ago22:15

22:15

Professor M Saiful Huq (Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, USA) and Dr Mostafa Aziz Sumon (Radiation Oncology, Kurmitola General Hospital, Dhaka, Bangladesh) discuss their Series on Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries.…

1
M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries 22:15

1y ago22:15

22:15

Professor M Saiful Huq (Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, USA) and Dr Mostafa Aziz Sumon (Radiation Oncology, Kurmitola General Hospital, Dhaka, Bangladesh) discuss their Series on Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries. Read the full Series: https:/…

1
Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma 15:07

1y ago15:07

15:07

Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma. Read the full Articles here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(…

1
In conversation with... Steven Horwitz 15:07

1y ago15:07

15:07

Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.By The Lancet

1
Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination 17:21

1+ y ago17:21

17:21

Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations. Read the full Article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00264-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanon…

1
May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics 40:45

1+ y ago40:45

40:45

May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics. Read the Commission: https:/…

1
In conversation with... Zachary Zumsteg 17:21

1+ y ago17:21

17:21

Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations.By The Lancet

1
In conversation with... May Abdel-Wahab and Andrew Scott 40:45

1+ y ago40:45

40:45

May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics.…

1
In conversation with... Kanwal Raghav 13:22

1+ y ago13:22

13:22

Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’.…

1
Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02) 13:22

1+ y ago13:22

13:22

Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’. Read the full article: https://ww…

1
In conversation with... Emmy Boerrigter 11:41

1+ y ago11:41

11:41

Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses.By The Lancet

1
Emmy Boerrigter on dose selection of novel anticancer drugs 11:41

1+ y ago11:41

11:41

Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00134-7?dgcid=buzzsprout_icw_podcast_generic_lan…

1
In conversation with... Hisham Mehanna and Sue Yom 36:56

1+ y ago36:56

36:56

Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and clinical trial endpoints.By The Lancet

1
Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations 36:56

1+ y ago36:56

36:56

Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and clinical trial endpoints. Tell us what you thought about this episode Continue this conversation on social! F…

1
In conversation with... Garth Strohbehn and Katie Lichter 24:08

1+ y ago24:08

24:08

Dr Garth Strohbehn (Veteran Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA) and Dr Katie Lichter (University of California, San Francisco, USA) discuss their papers on the environmental impact of cancer treatments and the public harms resulting from it.By The Lancet

1
Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment 24:08

1+ y ago24:08

24:08

Dr Garth Strohbehn (Veteran Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA) and Dr Katie Lichter (University of California, San Francisco, USA) discuss their papers on the environmental impact of cancer treatments and the public harms resulting from it. Tell us what you thought about this episode Continue this conversatio…

1
In conversation with... James Shultz, Ana Patricia Ortiz, and Leticia Nogueira 35:05

1+ y ago35:05

35:05

Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagno…

1
James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean 35:05

1+ y ago35:05

35:05

Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagno…

1
In conversation with... Bernardo Goulart 11:22

2y ago11:22

11:22

Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.By The Lancet

1
Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials 11:22

2y ago11:22

11:22

Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00040-8/fulltext?dgcid=buzzsprout_…

1
Interview With Atul Mehra, Co-founder VaayuShop AI | The Pre Money Show By Ruchit 59:29

2y ago59:29

59:29

In this episode of The Pre-Money Show, host Ruchit Sutaria interviews Atul Mehra, Co-Founder of VaayuSHop AI; an Enterprise AI – transformatiom start-up. It is building a middle-ware AI and Generative WAI stack that is built on top of existing IT infrastructure consist of ERP & CRM. Vaayu is raising $1mn in Pre-Seed funding/ Ruchit Email :Ruchit@pr…